)

Amylyx Pharmaceuticals (AMLX) investor relations material
Amylyx Pharmaceuticals Corporate Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Pipeline and development focus
Advancing three novel therapies: Avexitide for post-bariatric hypoglycemia (PBH), AMX0035 for Wolfram syndrome, and AMX0114 for ALS, all targeting diseases with high unmet needs.
All programs have received FDA designations (Breakthrough, Orphan, or Fast Track) and are supported by robust intellectual property portfolios.
Clinical development is led by an experienced team with a strong track record in rare disease commercialization.
Avexitide for post-bariatric hypoglycemia (PBH)
Avexitide is a first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations.
Phase 3 LUCIDITY trial began dosing in April 2025, with topline data expected in 1H 2026 and potential commercial launch in 2027.
Prior Phase 2 trials showed >50% reduction in hypoglycemic events, with consistent, dose-dependent effects and favorable safety profile.
PBH affects ~160,000 people in the U.S., is life-altering, and currently has no approved treatments.
Avexitide demonstrated significant improvement in glucose stabilization and reduction of insulin hypersecretion in both clinical and preclinical studies.
AMX0035 for Wolfram syndrome
AMX0035 is a fixed-dose combination targeting ER stress and mitochondrial dysfunction, central to Wolfram syndrome pathology.
Phase 2 HELIOS trial met its primary endpoint of improved pancreatic function at Week 24, with continued stabilization or improvement at Week 48.
Long-term data suggest benefit across multiple outcomes, including glycemic control, vision, and symptom burden, with a favorable safety profile.
Orphan Drug Designation granted in both the U.S. and EU; Phase 3 trial design to be informed by ongoing FDA discussions.
Wolfram syndrome is a rare, fatal disorder with no approved therapies, affecting ~3,000 people in the U.S.
Next Amylyx Pharmaceuticals earnings date

Next Amylyx Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage